Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 495 Results

Page 14 of 50« First «...12 131415 16...20 30 40...»Last »

June 16, 2022

DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York

June 9, 2022

DBV Technologies Announces Private Placement Financing of $194 Million

June 7, 2022

DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut- Allergic Toddlers

May 12, 2022

DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting

May 5, 2022

DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM)

May 2, 2022

DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq

May 2, 2022

DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results

April 25, 2022

DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments

April 21, 2022

Ordinary and Extraordinary General Meeting of May 12, 2022

March 21, 2022

Effect of Allergy Specialty Care of Healthcare Utilization Among Children with Peanut Allergy in the United States

Page 14 of 50« First «...12 131415 16...20 30 40...»Last »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Your California Privacy Rights

Scroll to Top